Biocept, Inc. (BIOC): Price and Financial Metrics
BIOC Price/Volume Stats
| Current price | $1.35 | 52-week high | $28.50 |
| Prev. close | $1.38 | 52-week low | $0.80 |
| Day low | $1.35 | Volume | 64,800 |
| Day high | $1.40 | Avg. volume | 718,387 |
| 50-day MA | $1.20 | Dividend yield | N/A |
| 200-day MA | $7.76 | Market Cap | 3.55M |
BIOC Stock Price Chart Interactive Chart >
BIOC POWR Grades
- BIOC scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.49% of US stocks.
- The strongest trend for BIOC is in Sentiment, which has been heading up over the past 81 days.
- BIOC ranks lowest in Stability; there it ranks in the 11th percentile.
BIOC Stock Summary
- BIOCEPT INC's market capitalization of $3,676,436 is ahead of merely 1.96% of US-listed equities.
- Revenue growth over the past 12 months for BIOCEPT INC comes in at -97.81%, a number that bests merely 0.88% of the US stocks we're tracking.
- The volatility of BIOCEPT INC's share price is greater than that of 98.71% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to BIOCEPT INC are IRIX, APDN, TIVC, LFLY, and ECOR.
- Visit BIOC's SEC page to see the company's official filings. To visit the company's web site, go to biocept.com.
BIOC Valuation Summary
- BIOC's EV/EBIT ratio is -0.3; this is 102.59% lower than that of the median Healthcare stock.
- BIOC's price/sales ratio has moved down 302.5 over the prior 117 months.
Below are key valuation metrics over time for BIOC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BIOC | 2023-09-22 | 2.7 | 12.8 | -0.1 | -0.3 |
| BIOC | 2023-09-21 | 2.7 | 12.8 | -0.1 | -0.3 |
| BIOC | 2023-09-20 | 2.9 | 13.4 | -0.1 | -0.3 |
| BIOC | 2023-09-19 | 2.9 | 13.4 | -0.1 | -0.3 |
| BIOC | 2023-09-18 | 2.9 | 13.8 | -0.1 | -0.3 |
| BIOC | 2023-09-15 | 3.2 | 15.2 | -0.1 | -0.3 |
BIOC Growth Metrics
- Its 2 year price growth rate is now at -63.51%.
- The year over year net income to common stockholders growth rate now stands at -19.3%.
- The 4 year net income to common stockholders growth rate now stands at -53.63%.
The table below shows BIOC's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 50.11914 | -7.483973 | -16.53611 |
| 2022-06-30 | 62.00164 | -4.093406 | -11.61581 |
| 2022-03-31 | 63.43781 | 1.914175 | -8.191292 |
| 2021-12-31 | 61.249 | 3.69 | -2.824 |
| 2021-09-30 | 65.7841 | 1.023974 | 2.049181 |
| 2021-09-30 | 65.7841 | 1.023974 | 3.100931 |
BIOC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BIOC has a Quality Grade of D, ranking ahead of 15.64% of graded US stocks.
- BIOC's asset turnover comes in at 1.212 -- ranking 14th of 81 Healthcare stocks.
- SSY, LH, and MGLN are the stocks whose asset turnover ratios are most correlated with BIOC.
The table below shows BIOC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 1.212 | 0.411 | -0.069 |
| 2021-03-31 | 1.070 | 0.374 | -0.312 |
| 2020-12-31 | 0.768 | 0.223 | -1.341 |
| 2020-09-30 | 0.379 | -0.323 | -4.029 |
| 2020-06-30 | 0.239 | -0.968 | -4.770 |
| 2020-03-31 | 0.290 | -0.903 | -5.429 |
BIOC Price Target
For more insight on analysts targets of BIOC, see our BIOC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $12.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Latest BIOC News From Around the Web
Below are the latest news stories about BIOCEPT INC that investors may wish to consider to help them evaluate BIOC as an investment opportunity.
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal MetastasesSAN DIEGO, September 21, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept’s proprietary CNSide assay in monitoring the response to therapy of LM, a |
Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today?Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Benzinga exclusively broke the story. Plus Therapeutics is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or melanomas with suspected leptomeningeal m |
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System CancersPlus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal fluid (CSF)-based tumor cell capture and enumeration platform, for patients receiving CNS radiotherapy. Under the terms of the agreement, CNSide developer Biocept has granted Plus Therapeutics a non-exclusive license to its CNSide cell enumeration assay for Plus' investigational therapy for leptomeningeal metastases |
Biocept Signs CNSide™ Licensing Agreement with Plus TherapeuticsSAN DIEGO, September 08, 2023--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the signing of a non-exclusive licensing agreement for CNSide™ with Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus), which expands the comprehensive laboratory services agreement between the two companies that was announced in June 2022. Plus is using CNSide in a clinical trial with their targeted radiotherapeutic to treat patients with carcinomas and/or |
Biocept to Participate in the H.C. Wainwright Global Investment ConferenceSAN DIEGO, September 05, 2023--Biocept, Inc. (Nasdaq: BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the Biocept presentation will be available on the Events & Presentation section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. |
BIOC Price Returns
| 1-mo | 46.45% |
| 3-mo | 11.57% |
| 6-mo | -86.76% |
| 1-year | -95.11% |
| 3-year | -99.01% |
| 5-year | -99.84% |
| YTD | -91.51% |
| 2022 | -85.36% |
| 2021 | -18.47% |
| 2020 | 55.24% |
| 2019 | -66.74% |
| 2018 | -95.85% |
Continue Researching BIOC
Want to see what other sources are saying about Biocept Inc's financials and stock price? Try the links below:Biocept Inc (BIOC) Stock Price | Nasdaq
Biocept Inc (BIOC) Stock Quote, History and News - Yahoo Finance
Biocept Inc (BIOC) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...